ORI Capital

ORI Capital is a venture capital firm founded in 2015 which invests in innovative early-stage biotech companies globally. Our mission is to be both financially successful for our investors and socially impactful to patients worldwide.

An Introduction to ORI Capital

We invest in the most promising innovations and disruptive technologies in the areas of diagnostics, drug delivery, and therapeutics focused on the disease areas with the highest mortality rates: cancer, cardiovascular and neurodegenerative diseases.

HKFSDC Hong Kong Success Stories Series - Hi Beautiful Minds (ORI Capital)

Simone Song, Founder of ORI Capital shares with Laurence Li, Chairman of FSDC her beautiful evolution from tumor battling to carrying out investment for saving lives, with scientific inspiration and the help of both Artificial and Human Intelligence.

Our Portfolio

Exited

Read More

The only company to date that can apply stem cell therapy to cure type 1 diabetes

Read More

World’s first fully humanized antibodies selection platform generating disease-modifying drugs

Listed

NASDAQ:ORTX

Read More

World’s leading gene therapy company targeting multiple diseases with limited or no existing treatment

The first ever high-volume biologic injector

The only company to date that can deliver drugs to pancreatic tumors using its innovative delivery device

First IVD company in tumor testing space making precision medicine the first-line treatment

The leading oncolytic virus company in Phase 3 bladder cancer

Developing CAR-T therapy focusing on brand new target for solid tumor

The world’s first cloud-based platform for AI medical imaging analysis

Cutting edge anti-aging nutraceutical company